Disease Progression: Various factors that influence HCV disease progression including steatosis, obesity, insulin resistance, diabetes, race/ethnicity, and general studies on disease progression.

 

        General

o       62. Risk of Hepato-Pancreatico-Biliary Tumors Following Hepatitis C Virus Infection: a Population-based Study on U.S. Veterans

o       280. The Envelope Protein of the Hepatitis C virus (E2) inhibits IL-2 Secretion from T lymphocytes

o       366. TLR-stimulated non-parenchymal liver cells are potent suppressors of HCV replication.

o       438a. A comparison of risk factors for intra- and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study.

o       M1779. Hyperlipidemia is very infrequent but is undertreated in chronic HCV. (updated, May 21)

o       M1783. Statins Improve ALT values in Chronic Hepatitis C Patients with Abnormal Values. (updated, May 21)

o       M1788. Liver disease in hepatitis C virus carriers found at the occasion of blood donation and outcomes with or without interferon treatment: A study on 1019 carriers followed for 5-10 years.

o       M1810. Serum Leptin Concentrations In Chronic Viral Hepatitis: A Clinical Approach.

o       M1820. Regulatory failure of serum prohepcidin levels in patients with hepatitis C

o       M1826. Hepatitis C and End Stage Renal Disease: A Global Survey.

o       M1829. Proteinuria in chronic HCV infection: a link for chronic kidney disease (CKD)?

o       M1836. Prevalence of Gallstones Among Persons With Hepatitis C Virus Infection In Pakistan (updated, May 23)

o       M1837. Co-infection with Cytomegalovirus in Chronic Hepatitis C Infection

o       M.1839 Early Occult Portal Hypertension in Chronic Hepatitis C (updated, May 28)

o       S1055 Comorbid Medical and Psychiatric Illness and Substance Abuse in HCV-Infected and Uninfected Veterans (updated, May 20)

o       S1225. Serum hepatocyte growth factor activator inhibitor type 1 is positively associated with hepatic fibrosis in patients with chronic hepatitis C virus infection.

 

        Extrahepatic Manifestations

o       M1838. Clinical Spectrum of Chronic Hepatitis C Virus-related Cryoglobulinemia in the US. (updated, May 21)

o       M1843. Associations among Susceptibility Factors for Human Porphyria Cutanea Tarda (updated, May 21)

o       M1853. Outcomes of pegylated interferon and ribavirin therapy for HCV patients with cryoglobulinemia as compared to patients without cryoglobulinemia.. (updated, May 21)

 

        Metabolic disorders

o       513. Associate Factors Of Nonalcoholic Fatty Liver Disease : Results From A Population-Based Study

o       M1819. The association of selected adipokines with hepatic steatosis in patients with chronic hepatitis C infection.

o       M1822. The association of adipokine levels with changes in steatosis following treatment in patients with chronic hepatitis C infection.

o       M1823. Chronic HCV Infection causes Insulin Resistance- A Meta-analysis. (updated, May 23)

o       M1831. Metabolic predictors of steatosis and fibrosis in chronic hepatitis C(HCV). (updated, May 21)

o       M1832. Lack of association between hepatitis C and diabetes mellitus: a case-control study. (updated, May 23)

o       S2158. Prevalence and associated factors of nonalcoholic liver fatty disease and metabolic syndrome: results from a cross-sectional study

o       T1064. Health Utility Assessment Using SF-6D and Health Utility Index (HUI) in Patients with Chronic Viral Hepatitis and Non-alcoholic Fatty Liver Disaese (NAFLD).

o       T1072. Outcome of Japanese patients with cirrhosis due to nonalcoholic steatohepatitis(NASH) and hepatitis C. (updated, May 22)

        Race

o       M1792. Clinical cirrhosis in chronic hepatitis c (CHC) varies by race-ethnicity. (updated, May 22)